These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 22331697)

  • 41. Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1.
    Mund JA; Park S; Smith AE; He Y; Jiang L; Hawley E; Roberson MJ; Mitchell DK; Abu-Sultanah M; Yuan J; Bessler WK; Sandusky G; Chen S; Zhang C; Rhodes SD; Clapp DW
    J Biol Chem; 2020 Jul; 295(29):9948-9958. PubMed ID: 32471868
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The activation of the WNT signaling pathway is a Hallmark in neurofibromatosis type 1 tumorigenesis.
    Luscan A; Shackleford G; Masliah-Planchon J; Laurendeau I; Ortonne N; Varin J; Lallemand F; Leroy K; Dumaine V; Hivelin M; Borderie D; De Raedt T; Valeyrie-Allanore L; Larousserie F; Terris B; Lantieri L; Vidaud M; Vidaud D; Wolkenstein P; Parfait B; Bièche I; Massaad C; Pasmant E
    Clin Cancer Res; 2014 Jan; 20(2):358-71. PubMed ID: 24218515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms.
    Perry A; Kunz SN; Fuller CE; Banerjee R; Marley EF; Liapis H; Watson MA; Gutmann DH
    J Neuropathol Exp Neurol; 2002 Aug; 61(8):702-9. PubMed ID: 12152785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mouse models of tumor development in neurofibromatosis type 1.
    Cichowski K; Shih TS; Schmitt E; Santiago S; Reilly K; McLaughlin ME; Bronson RT; Jacks T
    Science; 1999 Dec; 286(5447):2172-6. PubMed ID: 10591652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.
    Miller SJ; Rangwala F; Williams J; Ackerman P; Kong S; Jegga AG; Kaiser S; Aronow BJ; Frahm S; Kluwe L; Mautner V; Upadhyaya M; Muir D; Wallace M; Hagen J; Quelle DE; Watson MA; Perry A; Gutmann DH; Ratner N
    Cancer Res; 2006 Mar; 66(5):2584-91. PubMed ID: 16510576
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors.
    Upadhyaya M
    Front Biosci (Landmark Ed); 2011 Jan; 16(3):937-51. PubMed ID: 21196210
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
    Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
    Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
    Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
    Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Frequent MN1 Gene Mutations in Malignant Peripheral Nerve Sheath Tumor.
    Kinoshita I; Yamada Y; Kohashi K; Yamamoto H; Iwasaki T; Ishihara S; Toda YU; Ito Y; Susuki Y; Kawaguchi K; Ichiki T; Sato Y; Furue M; Nakashima Y; Oda Y
    Anticancer Res; 2020 Nov; 40(11):6221-6228. PubMed ID: 33109559
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.
    Williams KB; Largaespada DA
    Genes (Basel); 2020 Apr; 11(5):. PubMed ID: 32353955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genomic Status of
    Peacock JD; Pridgeon MG; Tovar EA; Essenburg CJ; Bowman M; Madaj Z; Koeman J; Boguslawski EA; Grit J; Dodd RD; Khachaturov V; Cardona DM; Chen M; Kirsch DG; Maina F; Dono R; Winn ME; Graveel CR; Steensma MR
    Cancer Res; 2018 Jul; 78(13):3672-3687. PubMed ID: 29720369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mechanisms of loss of heterozygosity in neurofibromatosis type 1-associated plexiform neurofibromas.
    Steinmann K; Kluwe L; Friedrich RE; Mautner VF; Cooper DN; Kehrer-Sawatzki H
    J Invest Dermatol; 2009 Mar; 129(3):615-21. PubMed ID: 18800150
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.
    Perrone F; Tabano S; Colombo F; Dagrada G; Birindelli S; Gronchi A; Colecchia M; Pierotti MA; Pilotti S
    Clin Cancer Res; 2003 Sep; 9(11):4132-8. PubMed ID: 14519636
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
    Friedrich RE; Beer C; Glatzel M; Hagel C
    Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
    Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
    Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.
    Perry A; Roth KA; Banerjee R; Fuller CE; Gutmann DH
    Am J Pathol; 2001 Jul; 159(1):57-61. PubMed ID: 11438454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. TAGLN expression is upregulated in NF1-associated malignant peripheral nerve sheath tumors by hypomethylation in its promoter and subpromoter regions.
    Park GH; Lee SJ; Yim H; Han JH; Kim HJ; Sohn YB; Ko JM; Jeong SY
    Oncol Rep; 2014 Oct; 32(4):1347-54. PubMed ID: 25109740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MicroRNA-204 critically regulates carcinogenesis in malignant peripheral nerve sheath tumors.
    Gong M; Ma J; Li M; Zhou M; Hock JM; Yu X
    Neuro Oncol; 2012 Aug; 14(8):1007-17. PubMed ID: 22718995
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
    Dang I; DeVries GH
    J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.